Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography
- Conditions
- Heart Failure
- Interventions
- Device: SonR CRT Optimization 'On'Device: SonR CRT Optimization 'Off'
- Registration Number
- NCT01869062
- Lead Sponsor
- MicroPort CRM
- Brief Summary
The main objective of the SONR-ECHO trial is to demonstrate that optimization of CRT parameters by SonR technology is able to increase the rate of CRT-D responders, based on significant LV reverse remodeling, as compared to Standard of Care settings.
This study will also evaluate the effectiveness of CRT-D SonR system as compared to Standard of care (SoC) programming methods in providing appropriate LV filling, as expected from the Ritter method.
- Detailed Description
This study will evaluate the effectiveness of CRT-D SonR system as compared to SoC programming methods to:
* Increase the rate of patients responding to CRT
* Provide appropriate hemodynamic cardiac effect, as expected from the Ritter method.
The identification of CRT responders, as defined by echocardiography, generally refers to a significant reduction of the LV End-Systolic Diameter (LVESD) and/or LVESV during Follow-Up (FUp).
Patients will be considered as responders to CRT if their LVESV decreased by \> 15% after 6 months of CRT therapy as compared to baseline. The percentage of CRT responders will be compared between the two study arms.
SoC is defined as the standard CRT system programming/optimization method currently used by physicians in study centers and any method may be used in the study if considered as routine practice in the study center.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 348
- Eligible for implantation of a CRT-D device according to published relevant ESC and CCS guidelines ;
- In Sinus Rhythm;
- Have reviewed, signed and dated an informed consent
- Previous implant with a pacemaker, an Implantable Cardioverter-Defibrillator or a CRT device (except upgrade from single chamber ICD with a fully functional defibrillation lead not under recall or surveillance);
- Persistent atrial arrhythmias (or cardioversion for Atrial Fibrillation) within the past month;
- Ventricular tachyarrhythmia secondary to reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;
- Incessant ventricular tachyarrhythmia;
- Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within the past 4 weeks;
- Correctable valvular disease that is the primary cause of heart failure;
- Mechanical heart valve or indication for valve repair or replacement;
- Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months);
- Post heart transplant (patients who are waiting for a heart transplant are allowed in the study);
- Already included in another clinical study that could confound the results of this study;
- Life expectancy less than 1 year;
- Inability to understand the purpose of the study;
- Unavailability for scheduled follow-up or refusal to cooperate;
- Sensitivity to 1 mg Dexamethasone Sodium Phosphate (DSP);
- Age of less than 18 years;
- Pregnancy;
- Drug addiction or abuse;
- Under guardianship
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SonR CRT Optimization 'On' SonR CRT Optimization 'On' CRT-D device with the SonR optimization algorithm programmed being 'on'. SonR CRT Optimization 'Off' SonR CRT Optimization 'Off' CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
- Primary Outcome Measures
Name Time Method CRT-responders rate increase based on LVESV decrease at M6 / baseline 6 months For the purpose of this study, CRT-responders are defined as patients experiencing a decrease in LVESV of 15% or more at M6 Fup as most clinical trials used.
The main objective of the SONR-ECHO trial is to show a minimum increase of CRT-responders rate of 15% (up to 72% or more) in the SonR study group as compared to SoC arm.
- Secondary Outcome Measures
Name Time Method A-wave truncation assessment at M6 6 months The Ritter's method attempts to optimize AV and VV timings in dual-chamber PM patients. According to this method, AV delay is optimal when LVFT is maximal and mitral valve closure only occurs after atrial systole (A-wave) is complete.
Trial Locations
- Locations (1)
Institut universitaire de Cardiologie et Pneumologie de Québec
🇨🇦Québec, Canada